2018-004882-15: Effect of the drug sacubitril/valsartan on physical performance in patients with hypertrophic cardiomyopathy Effekt des Medikaments Sacubitril/Valsartan auf die körperliche Leistungsfähigkeit bei Patienten mit hypertropher Kardiomyopathie |
|
|
| Not yet recruiting | 2 | 40 | Europe | Tablet, Entresto 50 mg (24 mg/26 mg), Entresto 100 mg (49 mg/51 mg), Entresto 200 mg (97 mg/103 mg) | University Hospital Regensburg, European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement no. 777204 | hypertrophic cardiomyopathy Hypertrophe Kardiomyopathie, Heart disease, that is characterized by an abnormal thickness of the heartmuscle Herzerkrankung, die durch eine Verdickung des Herzmuskels gekennzeichnet ist, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-006994-48: Empower the Heart of Patients with Terminal Cancer using Cardiac Medicines Trial |
|
|
| Not yet recruiting | 2 | 72 | Europe | Entresto, Solution for injection/infusion, Film-coated tablet, Ferinject®50 mg Eisen/ml, Jardiance® 10 mg, Procoralan® 5 mg, Procoralan® 7.5 mg, Entresto® 24 mg/26 mg, Entresto® 49 mg/51 mg, Entresto® 97 mg/103 mg | Universitätsklinikum Essen, Universitätsklinikum Essen | Patients with terminal cancer in palliative care, Patients with terminal cancer in palliative care, Diseases [C] - Cancer [C04] | | | | |
NCT02282358: Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma |
|
|
| Terminated | 1/2 | 7 | US | Mocetinostat | Memorial Sloan Kettering Cancer Center, MethylGene Inc. | Lymphoma, Relapsed and Refractory, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | 05/23 | 05/23 | | |
